Clinical trials: Language Impairment
Attention Deficit Hyperactivity Disorder, Dyslexia
Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia
This study will evaluate the effect of atomoxetine in treating Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms in children and adolescents with ADHD and comorbid reading disability (dyslexia)
- Trial name
- NCT00607919
- Testing
- Atomoxetine
- Where
- 16 sites in United States
- Volunteers
- 209 people
- Sponsor
- Eli Lilly and Company
Ischemic Stroke
Percutaneous Recanalization in Ischemic Stroke Management (PRIISM): A Feasibility Clinical Study
The primary study objective is to assess the feasibility of using the MindFrame System to safely and effectively restore blood flow in a thrombotic neurovascular occlusion in patients experiencing an ischemic stroke.
- Trial name
- PRIISM (NCT00810095)
- Testing
- MindFrame System
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- MindFrame, Inc.
Childhood-Onset Fluency Disorder (Stuttering)
Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely)
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 exploratory study in adult subjects with childhood onset fluency disorder.
- Trial name
- NCT04492956
- Testing
- Ecopipam
- Where
- 9 sites in United States
- Volunteers
- 68 people
- Sponsor
- Emalex Biosciences Inc.
Hearing Loss, Idiopathic Sudden Sensorineural
Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment
The primary objective of the trial is the confirmation of the efficacy of AM-111 in the recovery of severe to profound idiopathic sudden sensorineural hearing loss (ISSNHL).
- Trial name
- ASSENT (NCT02809118)
- Testing
- AM-111 0.4 mg/ml, AM-111 0.8 mg/ml
- Where
- 51 sites in United States, Canada and 1 more
- Volunteers
- 56 people
- Sponsor
- Auris Medical, Inc.
Attention Deficit Hyperactivity Disorder, Reading Disorder
Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD)
To test the hypothesis that a 4 week treatment with atomoxetine is more effective than placebo in patients with combined type Attention Deficit/Hyperactivity Disorder (ADHD), patients with only Reading Disorder, and patients with…
- Trial name
- NCT00191906
- Testing
- Atomoxetine Hydrochloride
- Where
- 5 sites in Belgium, Netherlands
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Broca Aphasia
Speech Hero Home Therapy for Aphasia
The investigators will run an at-home usability study of a newly developed speech therapy app called Speech Hero with 10 individuals with Broca's aphasia in the chronic stage of stroke.
- Trial name
- NCT04471935
- Testing
- At home Speech Hero therapy app
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Flint Rehabilitation Devices, LLC
Rehabilitation of Speech and Language Disorders, Speech Disorders
MyoVoice to Restore Natural, Hands-free Communication to Individuals With Vocal Impairments
This study will evaluate the ability of MyoVoice to replace natural speech. Referred to generally as an Augmentative and Alternative Communication (AAC) device, MyoVoice uses electrical signals recorded non-invasively from speech…
- Conditions
- Rehabilitation of Speech and Language Disorders, Speech Disorders, Speech, Alaryngeal, Communication Aids for Disabled
- Trial name
- NCT04762043
- Testing
- Experimental System: MyoVoice, Reference System: Electrolarynx
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Altec Inc.
Attention Deficit Hyperactivity Disorder, Dyslexia
Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia
This study will evaluate the effects of atomoxetine on brain activation during attention and reading tasks via functional Magnetic Resonance Imaging (fMRI) in participants ages 10 to 16 years old with ADHD and comorbid dyslexia
- Trial name
- NCT00716274
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Eli Lilly and Company